Saturday Rounds: Week of August 23–29, 2026

Biotech had an approval week that tested whether comparative human evidence still beats platform storytelling. Broad active-state RAS inhibition crossed from thesis to approved medicine when the FDA cleared Rasonque after a 500-patient randomized trial doubled median overall survival in previously treated metastatic pancreatic cancer,…